本次投资符合广药二期基金的投资方向，有利于扩大广药二期基金投资规模、分散投资风险及加快投资 步伐、提高投资效率，将加强本公司在创新药、现代中药、高端医疗器械等生物医药前沿领域的布局， 通过"投早、投小、投未来"，前瞻介入优质企业源头，培育孵化潜力企业，加快实现技术升级与价值链 延伸，推动本公司从传统业务模式向以科技创新驱动发展的模式转变，为高质量发展奠定坚实基础。 格隆汇12月22日丨白云山(600332.SH)公布，为扩大投资规模、分散投资风险及加快投资步伐、提高投 资效率，2025年12月22日，本公司第九届董事会第三十二次会议审议通过了《关于广州广药二期基金股 权投资合伙企业（有限合伙）认购广州广药广开创业投资基金合伙企业（有限合伙）有限合伙份额暨关 联交易的议案》，同意广药二期基金与广药资本、广州开发区投资基金管理有限公司（"广开基金"）合 作设立广药广开基金并签署《合伙协议》。 广药广开基金拟注册于广州市黄埔区，目标规模为3.00亿元，首期募集资金规模为2.00亿元，广药二期 基金拟出资0.975亿元，占比48.75%；广药资本拟出资0.025亿元，占比1.25%；广开基金拟出资1.00亿 元，占比 ...

Group 1 - The company announced that its wholly-owned subsidiary, Shanghai Shuo Fang Pharmaceutical Technology Co., Ltd., received a patent for a method to detect the fingerprint spectrum of ginkgo biloba decoction [1] - The acquisition of this patent is expected to enhance the company's intellectual property protection system and strengthen its core competitiveness through continuous innovation [1] - The company specializes in the research, development, production, and sales of traditional Chinese medicine, focusing on gynecological and urological medications, among other areas [1][2] Group 2 - The company adheres to a philosophy of combining traditional formulas with modern technology to improve clinical efficacy, ensuring a comprehensive approach to drug development [2] - The company’s product lineup includes unique varieties that cover multiple therapeutic areas, with a strong emphasis on clinical efficacy and inclusion in national basic drug and medical insurance directories [3] - The leading products, such as Kuntai capsules and Ningpitai capsules, are recognized as unique patented varieties with significant market barriers and pricing advantages [3] Group 3 - In the first half of 2025, the company achieved a revenue of 358 million yuan and a net profit of 5.77 million yuan attributable to shareholders [4]